Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.06−0.17 (-2.73%)
Close on Nov 13, 2026Market cap $492.63MP/E –Yield –
Phathom Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Phathom Pharmaceuticals's total assets was $345.02M at Sep 30, 2026. For fiscal 2025 it was $259.15M, down 31.5% from the year before. The highest annual figure on record is $413.84M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.15M | -31.5% |
| FY2024 | Dec 31, 2024 | $378.32M | -8.6% |
| FY2023 | Dec 31, 2023 | $413.84M | +151.1% |
| FY2022 | Dec 31, 2022 | $164.81M | -13.0% |
| FY2021 | Dec 31, 2021 | $189.43M | -35.8% |
| FY2020 | Dec 31, 2020 | $295.11M | +14.7% |
| FY2019 | Dec 31, 2019 | $257.18M | +28412.0% |
| FY2018 | Dec 31, 2018 | $902.00K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $345.02M | +43.6% |
| Q2 FY2026 | Jun 30, 2026 | $327.08M | +30.7% |
| Q1 FY2026 | Mar 31, 2026 | $305.12M | +3.7% |
| Q4 FY2025 | Dec 31, 2025 | $259.15M | -31.5% |
| Q3 FY2025 | Sep 30, 2025 | $240.29M | -37.9% |
| Q2 FY2025 | Jun 30, 2025 | $250.22M | -21.7% |
| Q1 FY2025 | Mar 31, 2025 | $294.21M | -17.5% |
| Q4 FY2024 | Dec 31, 2024 | $378.32M | -8.6% |
| Q3 FY2024 | Sep 30, 2024 | $387.04M | +63.3% |
| Q2 FY2024 | Jun 30, 2024 | $319.38M | +20.5% |
| Q1 FY2024 | Mar 31, 2024 | $356.50M | +147.6% |
| Q4 FY2023 | Dec 31, 2023 | $413.84M | +151.1% |
| Q3 FY2023 | Sep 30, 2023 | $236.99M | +17.4% |
| Q2 FY2023 | Jun 30, 2023 | $265.04M | +24.1% |
| Q1 FY2023 | Mar 31, 2023 | $144.01M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $164.81M | -13.0% |
| Q3 FY2022 | Sep 30, 2022 | $201.93M | -11.6% |
| Q2 FY2022 | Jun 30, 2022 | $213.50M | -0.5% |
| Q1 FY2022 | Mar 31, 2022 | $149.05M | -39.5% |
| Q4 FY2021 | Dec 31, 2021 | $189.43M | -35.8% |
| Q3 FY2021 | Sep 30, 2021 | $228.38M | -1.1% |
| Q2 FY2021 | Jun 30, 2021 | $214.58M | -15.0% |
| Q1 FY2021 | Mar 31, 2021 | $246.36M | -6.7% |
| Q4 FY2020 | Dec 31, 2020 | $295.11M | +14.7% |
| Q3 FY2020 | Sep 30, 2020 | $230.89M | +189.7% |
| Q2 FY2020 | Jun 30, 2020 | $252.42M | +27884.7% |
| Q1 FY2020 | Mar 31, 2020 | $263.92M | – |
| Q4 FY2019 | Dec 31, 2019 | $257.18M | – |
| Q3 FY2019 | Sep 30, 2019 | $79.71M | – |
| Q4 FY2018 | Dec 31, 2018 | $902.00K | – |
See a number that looks wrong?